Development of a quantitative NS1 antigen enzyme-linked immunosorbent assay (ELISA) for Zika virus detection using a novel virus-specific mAb

Stefanny Viloche Morales,Gabriela Mattoso Coelho,Taíssa Ricciardi-Jorge,Gisiane Gruber Dorl,Camila Zanluca,Claudia Nunes Duarte dos Santos

DOI: https://doi.org/10.1038/s41598-024-52123-2

IF: 4.6

2024-01-31

Scientific Reports

Abstract:Viruses from the Flaviviridae family, such as Dengue virus (DENV), Yellow fever virus (YFV), and Zika virus (ZIKV) are notorious global public health problems. ZIKV emergence in Polynesia and the Americas from 2013 to 2016 raised concerns as new distinguishing features set it apart from previous outbreaks, including its association with neurological complications and heightened disease severity. Virus detection is impaired as cross-reactivity to other closely related orthoflaviviruses is common among commercially available diagnostic kits. While non-structural protein 1 (NS1) has been used as an early marker of DENV and West Nile virus (WNV) infection, little is known about NS1 expression during ZIKV infection. In the present work, we developed a NS1 capture ELISA using a novel ZIKV-specific monoclonal antibody to study NS1 expression dynamics in vitro in mosquito and human cell lines. While detectable in culture supernatants, higher concentrations of NS1 were predominantly cell-associated. To our knowledge, this is the first report of NS1 detection in human cells despite viral clearance over time. Tests with human samples need to be conducted to validate the applicability of NS1 detection for diagnosis, but overall, the tools developed in this work are promising for specific detection of acute ZIKV infection.

multidisciplinary sciences

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop a specific quantitative NS1 antigen enzyme - linked immunosorbent assay (ELISA) for detecting Zika virus (ZIKV) infection. Specifically, the research aims to:

1. **Develop specific monoclonal antibodies**: Generate a new monoclonal antibody (mAb) against the ZIKV NS1 protein to improve the specificity and sensitivity of detection.
2. **Establish NS1 - capture ELISA**: Use this specific monoclonal antibody to establish a quantitative NS1 antigen - capture ELISA for detecting and quantifying the expression and secretion of the NS1 protein during ZIKV infection.
3. **Study NS1 expression dynamics**: Conduct infection experiments in mosquito cell lines (C6/36) and human cell lines (A549 and JEG - 3) to study the expression and secretion patterns of the NS1 protein at different time points.
4. **Evaluate the potential of NS1 as a diagnostic marker**: Explore whether the NS1 protein can be a reliable marker for early diagnosis of ZIKV infection and evaluate its feasibility in clinical applications.

Through these studies, the paper hopes to fill the current gap in the understanding of the expression and secretion mechanisms of the ZIKV NS1 protein and provide a scientific basis for the development of more effective ZIKV diagnostic methods.